| Name | Lansoprazole |
| Description | Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) |
| In vitro | Lansoprazole significantly attenuates intestinal damage induced by ischemia-reperfusion or indomethacin. Exogenous administration of Lansoprazole can prevent injury to the small intestine caused by ischemia-reperfusion or indomethacin. Lansoprazole inhibits acute inflammatory responses and mucosal injury in rats subjected to ischemia-reperfusion or indomethacin-induced damage. |
| In vivo | Lansoprazole is a potent antisecretory agent that inhibits gastric acid secretion by blocking the stomach's hydrogen/potassium adenosine triphosphatase (H+, K+-ATPase). It suppresses the upregulation of adhesion molecules in blood vessels, neutrophil activation, and the production of pro-inflammatory cytokines from activated endothelial cells. Furthermore, Lansoprazole induces the expression of various genes in gastric epithelial cells, including Phase II detoxifying enzymes (NADPH-quinone oxidoreductase, glutathione S-transferase) and antioxidative stress proteins (HO-1, thioredoxin reductase, and superoxide dismutase). In rat gastric epithelial cells, Lansoprazole upregulates HO-1 expression and exerts anti-inflammatory effects. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (135.37 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.41 mM), Sonication is recommended.
|
| Keywords | TSTQ | STZ | Protonpump | Proton Pump | Phospholipase | N-SMase | Lansoprazole | Inhibitor | inhibit | HFD | gastric | exosome | ELT | Bacterial | AG1749 | AG 1749 | acid | A65006 | A 65006 |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
